Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01224262 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001
A Phase 1 study of Influenza, sponsored by Liquidia Technologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 152
- Enrollment target
- 1
- Study location
NCT01224262 is a Phase 1 study of Influenza that has completed, run by Liquidia Technologies. The registered enrollment target is 152 participants, below the 36,803-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01224262, a Phase 1 study of Influenza, has completed, sponsored by Liquidia Technologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 152 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to evaluate the safety, tolerability, and immune response of LIQ001 mixed with a commercially available seasonal influenza vaccine (Fluzone) in two populations of subjects; healthy adult subjects 18 to 49 years of age and healthy elderly subjects 65 years of age or older.
Conditions Studied
Interventions
- BIOLOGICAL Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine)
- BIOLOGICAL LIQ001 (0.45mg)
- BIOLOGICAL LIQ001 (1.8mg)
Study Locations (1)
Florida
- Accelovance - Melbourne - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2010-09 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01224262
The ClinicalTrials.gov registry entry for NCT01224262 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,803-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The listed sponsor is Liquidia Technologies, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 3 interventions - of which Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) is the first listed.
NCT01224262 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT01224262 about?
NCT01224262 is a clinical study titled "A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001". This study is designed to evaluate the safety, tolerability, and immune response of LIQ001 mixed with a commercially available seasonal influenza vaccine (Fluzone) in two populations of subjects; healthy adult subjects 18 to 49 years of age and healthy elderly subjects 65 years of age or older.
What is the current status of trial NCT01224262?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 152 participants. The study started on 2010-09. Estimated completion is 2011-12.
What conditions does trial NCT01224262 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT01224262?
The interventions under investigation include: Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) (BIOLOGICAL), LIQ001 (0.45mg) (BIOLOGICAL), LIQ001 (1.8mg) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01224262?
This trial is sponsored by Liquidia Technologies, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01224262 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
pH1N1 Blinded Challenge Study
RECRUITING · Phase 1
-
A/Texas Flu Challenge
RECRUITING · Phase 1
-
First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics
RECRUITING · Phase 1
-
Influenza Human Challenge Model
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults
ACTIVE NOT RECRUITING · Phase 1
-
Pilot Influenza Challenge Study
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.